Overview
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
Status:
Completed
Completed
Trial end date:
2021-02-25
2021-02-25
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Addpharma Inc.Treatments:
Amlodipine
Telmisartan
Criteria
Inclusion Criteria:- Signed informed consent
- Other inclusions applied
Exclusion Criteria:
- orthostatic hypotension with symptom
- Other exclusions applied